Italia markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
50,81+0,09 (+0,18%)
Alla chiusura: 04:00PM EDT
50,65 -0,16 (-0,31%)
Dopo ore: 04:05PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente50,72
Aperto50,69
Denaro50,77 x 1200
Lettera50,78 x 800
Min-Max giorno50,62 - 50,85
Intervallo di 52 settimane13,11 - 51,06
Volume3.253.230
Media Volume2.138.614
Capitalizzazione3,626B
Beta (5 anni mensile)1,66
Rapporto PE (ttm)N/D
EPS (ttm)-2,01
Prossima data utili07 nov 2022 - 11 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A52,00
  • GlobeNewswire

    ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

    SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended J

  • GlobeNewswire

    ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

    SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (Internati

  • GlobeNewswire

    ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

    -- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board --SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. “With more than 25 years developing and refini